Eckert & Ziegler: Overproportional Revenue Growth

Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Final Results

30.03.2012 / 07:50

---------------------------------------------------------------------
Berlin, March 30, 2012. The Berlin company, Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist for isotope applications in medicine, science and industry, was able significantly to increase its sales and revenues in the just ended financial year 2011. With the revenue key figures, the company gained overall in double digits: the EBITDA grew by 15% to EUR 30.4 million, the EBIT by 38% to EUR 22.9 million and the income after taxes and minority interests by 11%, to EUR 10.4 million. This corresponds to earnings per share of EUR 1.98. Sales grew organically overall by 5% to EUR 116.2 million.

Due to the jump in earnings, the operative cash flow of the Group increased by a good third to over EUR 20.2 million (previous year: EUR 15.0 million). The net liquidity, or the surplus of the means of payment above the loan debts, grew by EUR 6.9 million to EUR 14.3 million.
The absolutely strongest growth area is again in the Isotope Products segment, in which the sales grew by EUR 3.8 million to EUR 54.6 million. This area profited from a robust demand for measurement technology components. Relatively strongest, by 13%, or EUR 3.0 million, was the growth in sales of radiopharmaceuticals. Primarily with contrast medium for cancer diagnosis, the Radiopharma segment reached a new annual record turnover of EUR 25.6 million. In the Radiation Therapy segment, the sales fell according to expectations by EUR 1.7 million to EUR 30.4 million, since turnover of past years from a system sale could not be repeated. In the Environmental Services segment, sales fell slightly by 2%, to EUR 5.5 million.

The Executive Board and the Supervisory Board will recommend a dividend of EUR 0.60 per dividend-entitled share (previous year: EUR 0.60) at the Annual General Meeting on May 24, 2012.

With some 600 employees, the Eckert & Ziegler Group is one of the world's largest providers of isotope-technical components for radiation therapy and nuclear medicine.

If you have any questions, please contact:

Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.de

End of Corporate News

---------------------------------------------------------------------
30.03.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------

Language: English Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Robert-Rössle-Str.10 13125 Berlin Germany Phone: 49 30 941084-138 Fax: 49 30 941084-112 E-mail: karolin.riehle@ezag.de Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin, Düsseldorf, Hamburg, München  
 
End of News    DGAP News-Service  
--------------------------------------------------------------------- 163138 30.03.2012